



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/617,955	07/14/2003	Ichiro Yamashita	61352-039	4459
7590 05/25/2005			EXAM	INER
Michael E. Fogarty McDERMOTT, WILL & EMERY			YU, MELANIE J	
600 13th Street, N.W.			ART UNIT	PAPER NUMBER
Washington, DC 20005-3096			1641	
		•	DATE MAILED: 05/25/2009	5

Please find below and/or attached an Office communication concerning this application or proceeding.

## Notice of Non-Compliant Amendment (37 CFR 1.121)

Application No.	Applicant(s)	
10/617,955	YAMASHITA, ICHIRO	
Examiner	Art Unit	
Melanie Yu	1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

The amendment document filed on 11 April 2005 is considered non-compliant! cause it has failed to meet the requirements of 37 CFR 1.121. In order for the amendment document to be compliant, correction of the following item(s) is required.

	1. Am	endments to the specification:  A. Amended paragraph(s) do not include markings.  B. New paragraph(s) should not be underlined.  C. Other
		stract:  A. Not presented on a separate sheet. 37 CFR 1.72.  B. Other
		<ul> <li>endments to the drawings:</li> <li>A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d).</li> <li>B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required.</li> <li>C. Other</li> </ul>
		endments to the claims:  A. A complete listing of all of the claims is not present.  B. The listing of claims does not include the text of all pending claims (including withdrawn claims)  C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended).  D. The claims of this amendment paper have not been presented in ascending numerical order.  E. Other: See Continuation Sheet.
r furthe	er eyn!	lanation of the amendment format required by 37 CFR 1 121, see MPEP 8 714 and the USPTO website a

For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714 and the USPTO website at http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/officeflyer.pdf.

## TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:

- 1. Applicant is given no new time period if the non-compliant amendment is an after-final amendment or an amendment filed after allowance. If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the entire corrected amendment must be resubmitted within the time period set forth in the final Office action.
- 2. Applicant is given one month, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the corrected section of the non-compliant amendment in compliance with 37 CFR 1.121, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a Quayle action.

Extensions of time are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action.

Failure to timely respond to this notice will result in:

Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action; or

Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental

amendment.

Continuation of 4(e) Other: Claim 1 recites substitutions of glycine and glutamine at positions 149 and 151, respectively, but does not recite a sequence identification number to which the substitutions are to be made. It is unclear to which sequence Applicant intends to make substitutions, and Applicant must therefore provide a SEQ ID number for examination in claim 1.